EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2023
TABLES
202
PAGES
299
EDITION
19
PRICE
USD 5450
CODE
MCP-6845
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Acute Heart Failure (AHF) Therapeutics Market to Reach $2.9 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2022-2030. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 2.6% CAGR and reach US$762.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the B-Blockers segment is readjusted to a revised 4.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $642.1 Million, While China is Forecast to Grow at 8.3% CAGR
The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$642.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 8.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -1.4% and -0.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately -1.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433.4 Million by the year 2030.
SELECT PLAYERS
Bayer AG; Bristol-Myers Squibb Company; Cardiorentis AG; CVie Therapeutics Limited; Cytokinetics, Inc.; Merck & Co., Inc.; Novartis AG; Orion Corporation; PhaseBio Pharmaceuticals, Inc.
SEGMENTS
» Product Type (Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics, Other Product Types) » End-Use (Home Care, Hospitals, Clinics, Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Market Outlook |
Recent Market Activity |
Sizing the AHF Market |
Acute Heart Failure - An Overview of the Disease and Available Therapeutics |
Diuretics and Vasodilators - The First Line Therapy for AHF |
Other Known Drugs for AHF - Lower Efficacy Thwarts Use |
Acute Heart Failure (AHF) Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
Bayer AG (Germany) |
Bristol-Myers Squibb Company (USA) |
Cardiorentis AG (Switzerland) |
CVie Therapeutics Limited (Taiwan) |
Cytokinetics, Inc. (USA) |
Merck & Co. (USA) |
Novartis AG (Switzerland) |
Orion Corporation (Finland) |
PhaseBio Pharmaceuticals, Inc. (USA) |
3. MARKET TRENDS & DRIVERS |
Conventional Therapies Leave Considerable Unmet Needs |
Novel Treatments Offer a Ray of Hope |
Key AHF Therapeutics in the Pipeline |
Serelaxin Nears Trial Readout form RELAX-AHF-2 |
Ularitide - A Novel Drug in Development for AHF |
The Litany of Drug Failures Expands, Emphasis on Prevention Grows |
Other Promising Drugs under Development |
Research Findings |
Kidney Dysfunction - Predictor of Acute Heart failure |
Genetic Influence on Heart Disease among African Americans |
Higher Body Mass Index - A Key Risk Factor for AHF |
Supplemental Oxygen Therapy May not be for All Cases of AHF |
Macro Growth Drivers |
Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics |
Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Cardiac Glycosides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Cardiac Glycosides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for B-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for B-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2021 & 2027 |
World Acute Heart Failure (AHF) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
JAPAN |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
CHINA |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
China Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
EUROPE |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
FRANCE |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
France Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
GERMANY |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
UNITED KINGDOM |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Spain Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Russia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
ASIA-PACIFIC |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
AUSTRALIA |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Australia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
INDIA |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
India Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
South Korea Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
LATIN AMERICA |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Argentina Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Brazil Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Mexico Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Rest of Latin America Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
MIDDLE EAST |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
IRAN |
Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Iran Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Israel Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Saudi Arabia Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
UAE Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Rest of Middle East Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
AFRICA |
Acute Heart Failure (AHF) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by Product Type - Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by Product Type - Percentage Breakdown of Value Sales for Cardiac Glycosides, B-Blockers, Calcium Channel Blockers, Diuretics and Other Product Types for the Years 2021 & 2027 |
Africa Recent Past, Current & Future Analysis for Acute Heart Failure (AHF) Therapeutics by End-Use - Home Care, Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa 7-Year Perspective for Acute Heart Failure (AHF) Therapeutics by End-Use - Percentage Breakdown of Value Sales for Home Care, Hospitals, Clinics and Other End-Uses for the Years 2021 & 2027 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com